[A24-01] Pembrolizumab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-positive) – Benefit assessment according to §35a Social Code Book V

Last updated 20.06.2024

Project no.:
A24-01

Commission:
Commission awarded on 03.01.2024 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adults with locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma whose tumours express PD-L1 (CPS ≥ 1); first-line treatment

Result of dossier assessment:

Added benefit not proven

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

DOI:

https://doi.org/10.60584/A24-01_en

Project no.	Title	Status
A15-33	Pembrolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)	Commission completed
A17-23	Pembrolizumab (classical Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V	Commission completed
A17-46	Pembrolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V	Commission completed
A18-67	Pembrolizumab (head and neck squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V	Commission completed
A18-89	Pembrolizumab (urothelial carcinoma, first line) - Benefit assessment according to §35a Social Code Book V (new scientific findings)	Commission completed
A19-29	Pembrolizumab (melanoma) - Benefit assessment according to §35a Social Code Book V	Commission completed
A19-30	Pembrolizumab (non-squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V	Commission completed
A19-31	Pembrolizumab (squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V	Commission completed
A19-99	Pembrolizumab (combination with axitinib, renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V	Commission completed
A21-35	Pembrolizumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V	Commission completed
A21-36	Pembrolizumab (colorectal cancer) - Benefit assessment according to §35a Social Code Book V	Commission completed
A21-34	Pembrolizumab (urothelial carcinoma first line treatment) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)	Commission completed
A21-144	Pembrolizumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V	Commission completed
A21-145	Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) - Benefit assessment according to §35a Social Code Book V	Commission completed
A21-163	Pembrolizumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V	Commission completed
A21-164	Pembrolizumab (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V	Commission completed
A22-63	Pembrolizumab (breast cancer) - Benefit assessment according to § 35a Social Code Book V	Commission completed
A22-73	Pembrolizumab (melanoma, advanced) – Benefit assessment according to § 35a SGB V	Commission completed
A22-72	Pembrolizumab (melanoma, adjuvant) – Benefit assessment according to § 35a SGB V	Commission completed
A22-76	Pembrolizumab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V	Commission completed
A22-77	Pembrolizumab (gastric cancer) – Benefit assessment according to §35a Social Code Book V	Commission completed
A22-78	Pembrolizumab (small bowel cancer) – Benefit assessment according to §35a Social Code Book V	Commission completed
A22-71	Pembrolizumab (renal cell carcinoma) – Benefit assessment according to § 35a SGB V	Commission completed
A22-70	Pembrolizumab (cervical cancer) – Benefit assessment according to § 35a SGB V	Commission completed
A22-79	Pembrolizumab (bile cancer) – Benefit assessment according to § 35a SGB V	Commission completed
A22-75	Pembrolizumab (colorectal cancer) – Benefit assessment according to § 35a SGB V	Commission completed
A19-100	Pembrolizumab (head and neck squamous cell carcinoma, monotherapy) - Benefit assessment according to §35a Social Code Book V	Commission completed
A19-101	Pembrolizumab (head and neck squamous cell carcinoma, combination therapy) - Benefit assessment according to §35a Social Code Book V	Commission completed
A24-03	Pembrolizumab (biliary cancer) – Benefit assessment according to §35a Social Code Book V	Commission completed
A24-02	Pembrolizumab (gastric cancer, HER2-negative) – Benefit assessment according to §35a Social Code Book V	Commission completed
A24-58	Pembrolizumab (gastric and gastro-oesophageal junction adenocarcinoma, HER2-positive) – Addendum to Project A24-01	Commission completed
A24-46	Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to § 35a Social Code Book V	Commission completed
A24-47	Pembrolizumab (NSCLC, adjuvant) – Benefit assessment according to § 35a Social Code Book V	Commission completed

Federal Joint Committee (G-BA)

2024-06-20 A G-BA decision was published.

G-BA documents on this decision

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form